Patents by Inventor Kenneth Bordeau
Kenneth Bordeau has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7994168Abstract: The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicaments.Type: GrantFiled: February 21, 2007Date of Patent: August 9, 2011Assignee: Sanofi-Aventis Deutschland GmbHInventors: Petra Lennig, Siegfried Stengelin, Thomas Klabunde, Matthias Gossel, Pavel Safar, James Spoonamore, Gregory Merriman, Joseph T Klein, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang, Martin Smrcina
-
Patent number: 7652007Abstract: Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for the preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. Compounds of the formula I in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.Type: GrantFiled: February 13, 2004Date of Patent: January 26, 2010Assignee: Sanofi-Aventis Deutschland GmbHInventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Petra Stahl, Pavel Safar, James Spoonamore, Martin Smrcina, Joseph Klein, Gregory Merriman, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang
-
Patent number: 7550469Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: GrantFiled: December 21, 2006Date of Patent: June 23, 2009Assignee: Aventis Pharmaceuticals Inc.Inventors: James A Hendrix, Joseph T Strupczewski, Kenneth Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerle, John G Jurcak, Harpal Gill, Franz J Weiberth, Thaddeus Nieduzak, Sharon Anne Jackson, Xu-Yang Zhao, Paul Justin Mueller
-
Publication number: 20070265278Abstract: The present invention is directed to a compound of Formula (XVI): (please replace Formula (I) with Formula (XVI) as shown below) wherein R, R2, R3, R4, R5, R6, R7 and n are as defined herein, or a pharmaceutically acceptable salt, hydrate, or solvate thereof, a pharmaceutically acceptable prodrug thereof, or a pharmaceutically acceptable salt, hydrate or solvate of the prodrug, a pharmaceutical composition comprising a pharmaceutically effective amount of one or more compounds according to Formula (XVI) in admixture with a pharmaceutically acceptable carrier, a method of treating a patient suffering from a PGD2-mediated disorder including, but not limited to, allergic disease (such as allergic rhinitis, allergic conjunctivitis, atopic dermatitis, bronchial asthma and food allergy), systemic mastocytosis, disorders accompanied by systemic mast cell activation, anaphylaxis shock, bronchoconstriction, bronchitis, urticaria, eczema, diseases accompanied by itch (such as atopic dermatitis and urticaria), diseType: ApplicationFiled: July 25, 2007Publication date: November 15, 2007Applicant: Aventis Pharmaceuticals Inc.Inventors: Keith HARRIS, Hans-Jochen Lang, Rose Mathew, Stephen Shimshock, Thaddeus Nieduzak, Sharon Jackson, Zhaoxia Yang, Kenneth Bordeau
-
Publication number: 20070197539Abstract: The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives substituted with amino acids, and to the physiologically tolerated salts thereof, processes for their preparation and their use as medicamentsType: ApplicationFiled: February 21, 2007Publication date: August 23, 2007Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBHInventors: Petra Lennig, Siegfried Stengelin, Thomas Klabunde, Matthias Gossel, Pavel Safar, Martin Smrcina, James Spoonamore, Gregory Merriman, Joseph Klein, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang
-
Publication number: 20070161641Abstract: The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates is to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: ApplicationFiled: March 5, 2007Publication date: July 12, 2007Applicant: Aventis Pharmaceuticals Inc.Inventors: James Hendrix, Horst Hemmerle, Matthias Urmann, Gregory Shutske, Joseph Strupczewski, Kenneth Bordeau, John Jurcak, Thaddeus Nieduzak, Sharon Jackson, Paul Angell, James Carey, George Lee, David Fink, Jean-Francois Sabuco, Yulin Chiang, Nicola Collar
-
Publication number: 20070142351Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: ApplicationFiled: December 21, 2006Publication date: June 21, 2007Applicant: Aventis Pharmaceuticals Inc.Inventors: James Hendrix, Joseph Strupczewski, Kenneth Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerte, John Jurcak, Harpal Gill, Franz Weiberth, Thaddeus Nieduzak, Sharon Jackson, Xu-Yang Zhao, Paul Mueller
-
Publication number: 20070099955Abstract: The present invention provides compounds of formula I: a stereoisomer or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2, R3, R4, X and n are defined as defined herein. Additionally, a method for treating dopamine-related neurological disorders selected form the group consisting of neurological, psychological, cardiovascular, cognitive or attention disorders, substance abuse and addictive behavior, or a combination thereof, comprising administering to a patient in need of such treatment a therapeutically effective amount of compounds of formula I.Type: ApplicationFiled: October 24, 2006Publication date: May 3, 2007Applicant: AVENTIS PHARMACEUTICALS INC.Inventors: Gregory Shutske, Keith Harris, Kenneth Bordeau, Michael Angelastro, Stanly John, Joseph Klein, Jinqi Lu, Catherine Bomont
-
Publication number: 20050107389Abstract: The invention relates to heterocyclic substituted amide derivatives that display selective binding to dopamine D3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders.Type: ApplicationFiled: October 7, 2004Publication date: May 19, 2005Applicant: Aventis Pharmaceuticals Inc.Inventors: James Hendrix, Joseph Strupczeski, Kenneth Bordeau, Matthias Urmann, Gregory Shutske, Horst Hemmerle, John Jurcak, Harpal Gill, Franz Weiberth, Thaddeus Nieduzak, Sharon Jackson, Xu-Yang Zhao, Paul Mueller
-
Publication number: 20050085483Abstract: Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for the preparation and their use as medicaments The invention relates to substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and processes for preparing them are described. The compounds are suitable for example as anorectic agents.Type: ApplicationFiled: February 13, 2004Publication date: April 21, 2005Applicant: AVENTIS PHARMA DEUTSCHLAND GMBHInventors: Stefanie Flohr, Siegfried Stengelin, Matthias Gossel, Thomas Klabunde, Petra Stahl, Pavel Safar, James Spoonamore, Martin Smrcina, Joseph Klein, Gregory Merriman, Brian Whiteley, Carolina Lanter, Kenneth Bordeau, Zhaoxia Yang
-
Patent number: 5041445Abstract: This invention relates to 3-[1-thiazolidinylbutyl-4-piperazinyl]-1H-indazoles of the formula ##STR1## where R.sub.1 and R.sub.2 are each independently hydrogen or loweralkyl or R.sub.1 and R.sub.2 taken together with the carbon atom to which they are attached form a cyclopentane, cyclohexane or cycloheptane ring; R.sub.3 and R.sub.4 are independently hydrogen or loweralkyl or R.sub.3 and R.sub.4 taken together with the carbon atom to which they are attached form a cyclopentane, cyclohexane or cycloheptane ring; R.sub.5 is hydrogen, loweralkyl, alkanoyl or aroyl; X is hydrogen, halogen, loweralkyl or alkoxy; m is an integer of 1 to 3, the pharmaceutically acceptable acid addition salts thereof and where applicable, the optical, geometrical and stereoisomers and racemic mixtures thereof. The compounds of this invention are useful as antipsychotic agents.Type: GrantFiled: May 21, 1990Date of Patent: August 20, 1991Assignee: Hoechst-Roussel Pharmaceuticals IncorporatedInventors: Nicholas J. Hrib, Joseph T. Strupczewski, John G. Jurcak, Kenneth Bordeau